EurekaMag.com logo
+ Translate

The continued occurrence of primary Pneumocystis carinii pneumonia despite the availability of prophylaxis


, : The continued occurrence of primary Pneumocystis carinii pneumonia despite the availability of prophylaxis. Clinical Infectious Diseases 24(3): 522-523


(PDF same-day service: $19.90)

Accession: 002980820

PMID: 9114218

DOI: 10.1093/clinids/24.3.522

Submit PDF Full Text: Here


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Ewig, S.; Rockstroh, J.K.; Schäfer, H.; Leutner, C.; Pickenhain, A.; Lüderitz, B., 1996: HIV-associated Pneumocystis carinii pneumonia, primary pentamidine inhalation prophylaxis notwithstanding. Are there differences with Pneumocystis carinii pneumonia without prophylaxis?. To study the effect of pentamidine aerosol inhalation, known to be effective and well tolerated in the primary prevention of HIV-associated Pneumocystis carinii pneumonia (PCP), on the severity, on clinical and radiological findings and prognosis...

Simonds, R.J.; Lindegren, M.L.; Thomas, P.; Hanson, D.; Caldwell, B.; Scott, G.; Rogers, M., 1995: Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group. Pneumocystis carinii pneumonia (PCP) remains a common and often fatal opportunistic infection among children infected with the human immunodeficiency virus (HIV). HIV-infected infants between three and six months of age are particularly vulnerable...

Stoehr, A.; Plettenberg, A.; Albrecht, H.; Stellbrink, H.J.; Meigel, W.; Begemann, F., 1994: Primary and secondary prophylaxis of Pneumocystis carinii pneumonia with pentamidine aerosol. Efficacy, side effects and frequency of extrapulmonary Pneumocystis carinii manifestation. A retrospective study was performed in 544 HIV-positive patients (42 women, 502 men, mean age 35 yr) in Hamburg, Germany, showing CD4 lymphocyte counts <200/ micro l or after their cure of P. carinii pneumonia, who received 300 mg pentamidine a...

Buskin, S.E.; Newcomer, L.M.; Koutsky, L.A.; Hooton, T.M.; Spach, D.H.; Hopkins, S.G., 1999: Effect of trimethoprim-sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis on bacterial illness, Pneumocystis carinii pneumonia, and death in persons with AIDS. To measure the effect of trimethoprim-sulfamethoxazole (TMP-SMX) in preventing bacterial illness, P. carinii pneumonia (PCP) and death in patients with AIDS, a retrospective medical record review was conducted including 1078 subjects who were obse...

Tarabey, R., 1993: Primary prophylaxis against Pneumocystis carinii pneumonia. New England Journal of Medicine 328(20): 1499-1499

Ruf B.; Pohle H.D.; Schuermann D., 1989: Primary and secondary prophylaxis against pneumocystis carinii pneumonia with fansidar. Morisset, R A (Ed ) Ve Conference Internationale Sur Le Sida: Le Defi Scientifique Et Social; V International Conference on Aids: The Scientific And Social Challenge; Montreal, Quebec, Canada, June 4-9, 1262p International Development Research Centre: Ottawa, Ontario, Canada Illus Paper 290

Mussini, C.; Pezzotti, P.; Govoni, A.; Borghi, V.; Antinori, A.; Monforte, A.D.arminio; D.L.ca, A.; Mongiardo, N.; Cerri, M.C.iara; Chiodo, F.; Concia, E.; Bonazzi, L.; Moroni, M.; Ortona, L.; Esposito, R.; Cossarizza, A.; D.R.enzo, B., 2000: Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type 1-infected patients: The changes in opportunistic prophylaxis study. A multicenter open, randomized, controlled trial was conducted to determine whether primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis can be discontinued in patients infected with human immunodeficiency virus type...

Mussini, C.; Pezzotti, P.; Govoni, A.; Borghi, V.; Antinori, A.; d'Arminio Monforte, A.; D.L.ca, A.; Mongiardo, N.; Cerri, M.C.; Chiodo, F.; Concia, E.; Bonazzi, L.; Moroni, M.; Ortona, L.; Esposito, R.; Cossarizza, A.; D.R.enzo, B., 2000: Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study. A multicentre open, randomized, controlled trial was started in January 1998 to determine whether primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis can be discontinued in patients at 41 clinical centres in Italy a...

May T.; Hoen B.; Amiel C.; Kures L.; Canton P., 1991: Does primary prophylaxis alter the face of pneumocystis carinii pneumonia pcp in aids. Istituto Superiore Di Sanita Vii International Conference on Aids: Science Challenging Aids; Florence, Italy, June 16-21, 464p (Vol 1); 460p (Vol 2) Istituto Superiore Di Sanita: Rome, Italy Paper : 230b

Schuermann, D.; Gruenewald, T.; Bergmann, F.; Ruf, B., 1993: Fansidar for the primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasma encephalitis. IXTH INTERNATIONAL CONFERENCE ON AIDS AND THE IVTH STD WORLD CONGRESS [Author] IXth International Conference on AIDS in affiliation with the IVth STD World Congress : 57